Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.52 |
| ▸ | PRKACA | P17612 | 2/20 | 0.51 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.51 |
| ▸ | AHCY | P23526 | 3/20 | 0.51 |
| ▸ | MARS1 | P56192 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | GSK3A | P49840 | 1/20 | 0.49 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3414711 | 1.00 | ADORA3 (0.55) | ADORA3HSP90B1EGFRERBB2PRKACA | |
| SCHEMBL2483993 | 0.93 | ADORA3 (0.60) | ADORA3HSP90B1PRKACAMARS1ADORA1 | |
| SCHEMBL10587742 | 0.87 | AHCY (0.61) | ADORA3HSP90B1PRKACAEHMT1AHCY | |
| SCHEMBL6536429 | 0.87 | HSP90B1 (0.57) | HSP90B1PRKACAAHCYMARS1ADORA1 | |
| SCHEMBL10586454 | 0.87 | PRKACA (0.67) | ADORA3HSP90B1PRKACAEHMT1AHCY | |
| SCHEMBL6536155 | 0.87 | PRKACA (0.67) | ADORA3HSP90B1PRKACAEHMT1AHCY | |
| SCHEMBL21999054 | 0.84 | ADORA3 (0.56) | ADORA3EGFRERBB2EHMT1AHCY | |
| SCHEMBL12360836 | 0.84 | ADORA3 (0.56) | ADORA3EGFRERBB2EHMT1AHCY | |
| SCHEMBL12376385 | 0.84 | ADORA3 (0.56) | ADORA3EGFRERBB2EHMT1AHCY | |
| SCHEMBL12801365 | 0.83 | GAA (0.54) | ADORA3HSP90B1EHMT1AHCYADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011047982-A2 | USE OF ADENOSINE AND/OR OF ONE OF ITS DERIVATIVES AS AGENT FOR THE TREATMENT OF HUMAN PERSPIRATION | L'OREAL (FR) | 2011-04-28 | — | — | WO | disclosed |
| EP-1878470-B1 | Skin depigmentation method | OREAL (FR) | 2009-03-11 | — | — | EP | disclosed |
| EP-1878470-A1 | Skin depigmentation method | L'Oréal (FR) | 2008-01-16 | — | — | EP | disclosed |
| US-20070258921-A1 | PROCESS FOR DEPIGMENTING THE SKIN | L'OREAL (FR) | 2007-11-08 | — | — | US | disclosed |
| US-20070258921-A1 | PROCESS FOR DEPIGMENTING THE SKIN | L'OREAL (FR) | 2007-11-08 | — | — | US | disclosed |
| EP-1847547-A1 | Anti-wrinkle cosmetic composition | L'Oréal (FR) | 2007-10-24 | — | — | EP | disclosed |
| US-20070237734-A1 | ANTI-WRINKLE COSMETIC COMPOSITION | L'OREAL (FR) | 2007-10-11 | — | — | US | disclosed |
| US-20070237734-A1 | ANTI-WRINKLE COSMETIC COMPOSITION | L'OREAL (FR) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070258921-A1 | PROCESS FOR DEPIGMENTING THE SKIN | TYR, CUTA, NQO1 | ADORA3 4081/4885HSP90B1 3263/4885EGFR 4705/4885 |
| US-20070237734-A1 | ANTI-WRINKLE COSMETIC COMPOSITION | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885HSP90B1 4413/4885EGFR 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.